Brief: Syndax Announces PDUFA Action Date Extension For Revumenib NDA For Relapsed Or Refractory KMT2Ar Acute Leukemia
29/07/2024 12:17
July 29 (Reuters) - Syndax Pharmaceuticals Inc SNDX.O :
* SYNDAX ANNOUNCES PDUFA ACTION DATE EXTENSION FOR REVUMENIB
NDA
FOR RELAPSED OR REFRACTORY KMT2AR ACUTE LEUKEMIA
* SYNDAX PHARMACEUTICALS INC: NEW PDUFA ACTION DATE OF
DECEMBER 26
* SYNDAX PHARMACEUTICALS INC: NEW PDUFA ACTION DATE OF
DECEMBER
26, 2024 ALLOWS FDA ADDITIONAL TIME TO COMPLETE THEIR REVIEW
Source text for Eikon: ID:nPn9hxGRXa
Further company coverage: SNDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Syndax Pharmaceuticals
See all newsBrief: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million